Trials / Terminated
TerminatedNCT00282230
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Prograf®/FK778 and Prograf®/MMF in De Novo Kidney Transplant Recipients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FK778 |
Timeline
- Start date
- 2003-11-01
- Completion
- 2005-10-01
- First posted
- 2006-01-26
- Last updated
- 2012-06-07
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00282230. Inclusion in this directory is not an endorsement.